Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MOdel-Informed Precision Dosing (MIPD) of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - An Independent Randomized Controlled Trial

NCT06788340 is registered in ClinicalTrials.gov with Odense University Hospital as lead sponsor.

NCT NCT06788340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MOdel-Informed Precision Dosing (MIPD) of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - An Independent Randomized Controlled Trial
Lead sponsor
Odense University Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
November 1, 2027
Enrollment
166 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, inflammatory bowel diseases, ulcerative colitis